EMA marks European Antibiotic Awareness Day with renewed commitment to tackle AMR

18 November 2015

The European Medicines Agency (EMA) has reinforced its commitment to help combat antimicrobial resistance (AMR) to mark European Antibiotic Awareness Day (EAAD) 2015.

AMR is one of the most serious public health threats globally with infections caused by multidrug-resistant bacteria estimated to kill 25,000 people every year in Europe alone.

In a three-pronged approach, the EMA stresses the importance of developing new treatments, promoting responsible use of antibiotics and collecting robust data to inform public health policies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK